» Articles » PMID: 31697823

Therapy-induced Mutations Drive the Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia

Abstract

To study the mechanisms of relapse in acute lymphoblastic leukemia (ALL), we performed whole-genome sequencing of 103 diagnosis-relapse-germline trios and ultra-deep sequencing of 208 serial samples in 16 patients. Relapse-specific somatic alterations were enriched in 12 genes (NR3C1, NR3C2, TP53, NT5C2, FPGS, CREBBP, MSH2, MSH6, PMS2, WHSC1, PRPS1, and PRPS2) involved in drug response. Their prevalence was 17% in very early relapse (<9 months from diagnosis), 65% in early relapse (9-36 months), and 32% in late relapse (>36 months) groups. Convergent evolution, in which multiple subclones harbor mutations in the same drug resistance gene, was observed in 6 relapses and confirmed by single-cell sequencing in 1 case. Mathematical modeling and mutational signature analysis indicated that early relapse resistance acquisition was frequently a 2-step process in which a persistent clone survived initial therapy and later acquired bona fide resistance mutations during therapy. In contrast, very early relapses arose from preexisting resistant clone(s). Two novel relapse-specific mutational signatures, one of which was caused by thiopurine treatment based on in vitro drug exposure experiments, were identified in early and late relapses but were absent from 2540 pan-cancer diagnosis samples and 129 non-ALL relapses. The novel signatures were detected in 27% of relapsed ALLs and were responsible for 46% of acquired resistance mutations in NT5C2, PRPS1, NR3C1, and TP53. These results suggest that chemotherapy-induced drug resistance mutations facilitate a subset of pediatric ALL relapses.

Citing Articles

is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort.

Krstevska Bozhinovikj E, Matevska-Geshkovska N, Staninova Stojovska M, Gjorgievska E, Jovanovska A, Kocheva S Balkan J Med Genet. 2025; 27(2):5-12.

PMID: 40070861 PMC: 11892942. DOI: 10.2478/bjmg-2024-0020.


SUMOylation inhibition potentiates the glucocorticoid receptor to program growth arrest of acute lymphoblastic leukemia cells.

Valima E, Varis V, Bureiko K, Lempiainen J, Schroderus A, Oksa L Oncogene. 2025; .

PMID: 39953147 DOI: 10.1038/s41388-025-03305-3.


Inhibiting H3K27 Demethylases Downregulates CREB-CREBBP, Overcoming Resistance in Relapsed Acute Lymphoblastic Leukemia.

Lazaro-Navarro J, Alcon C, Dorel M, Alasfar L, Bastian L, Baldus C Cancer Med. 2025; 14(1):1-7.

PMID: 39791538 PMC: 11719120. DOI: 10.1002/cam4.70596.


Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia.

Navas-Acosta J, Hernandez-Sanchez A, Gonzalez T, Villaverde Ramiro A, Santos S, Miguel C Cancers (Basel). 2025; 16(24.

PMID: 39766099 PMC: 11674736. DOI: 10.3390/cancers16244200.


Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center.

Kebede A, Garfinkle E, Mathew M, Varga E, Colace S, Wheeler G Front Oncol. 2024; 14:1498409.

PMID: 39687881 PMC: 11647012. DOI: 10.3389/fonc.2024.1498409.


References
1.
Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S . A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. PMC: 2851638. DOI: 10.1016/j.cell.2010.02.027. View

2.
Steuer C, Ramalingam S . Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?. J Clin Oncol. 2018; 36(7):631-632. DOI: 10.1200/JCO.2017.76.8770. View

3.
Mullighan C, Zhang J, Kasper L, Lerach S, Payne-Turner D, Phillips L . CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011; 471(7337):235-9. PMC: 3076610. DOI: 10.1038/nature09727. View

4.
Kaspers G, Smets L, Pieters R, van Zantwijk C, van Wering E, Veerman A . Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood. 1995; 85(3):751-6. View

5.
Papaemmanuil E, Rapado I, Li Y, Potter N, Wedge D, Tubio J . RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014; 46(2):116-25. PMC: 3960636. DOI: 10.1038/ng.2874. View